

HETEROCYCLES, Vol. 83, No. 2, 2011, pp. 371 - 383. © The Japan Institute of Heterocyclic Chemistry
Received, 9th November, 2010, Accepted, 9th December, 2010, Published online, 27th December, 2010
DOI: 10.3987/COM-10-12101

THE SYNTHESIS OF SOME DERIVATIVES BASED ON THE 4-BENZYL-1*H*-PYRAZOLE-3,5-DIAMINE CORE

Lukáš Jedinák,^a Vladimír Kryštof,^b and Petr Cankar^{a*}

^aDepartment of Organic Chemistry, Palacký University, 17. listopadu 1192/12, 771 46 Olomouc, Czech Republic. E-mail: cankar@orgchem.upol.cz
Tel: +420585634437, Fax: +420585634465

^bLaboratory of Growth Regulators, Institute of Experimental Botany, AS CR and Palacký University, Slechtitelu 11, 783 71 Olomouc, Czech Republic


Abstract – The three-step synthesis of 4-benzyl-1*H*-pyrazole-3,5-diamines **2** from commercially available aldehydes **3** is given. The Knoevenagel condensation was utilized to assemble the initial carbon framework, resulting in the benzylidenemalononitriles **4** which were directly transformed by the reduction of the electron deficient C=C bond to benzylmalononitriles **5**. Subsequent cycloaddition of hydrazine with **5** afforded the desired pyrazoles **2**. Due to the high similarity with 4-arylazo-1*H*-pyrazole-3,5-diamines, the biological activities of the 4-benzyl-1*H*-pyrazole-3,5-diamines **2** were evaluated while focusing on the inhibition of cyclin-dependent kinases (CDKs), but no significant results were obtained.

In the last decade, protein kinases became an important class of drug targets for the pharmaceutical industry for the treatment of proliferative disorders such as cancer and inflammation.¹⁻⁴ The successful development of these molecular inhibitors resulted in the launch of several drug candidates that are currently on the market. Some examples of this class of drug that are commercially available include imatinib, dasatinib and nilotinib.⁵ This selection, of course, only partially illustrates the vast amount of research completed in the area of protein kinase inhibitors.

A few years ago, we reported that the 4-arylazopyrazole-3,5-diamine derivatives **1** (Scheme 1) showed significant inhibitory activity against cyclin-dependent kinases (CDKs).⁶ The most potent derivative, CAN508, displayed selectivity toward CDK9.⁶ Inhibition of CDK9, which is the catalytic subunit of

conditions, benzaldehydes **3a**, **3b** and **3c** were chosen for a model study. THF was used as the solvent because a wide range benzaldehyde derivatives are typically very soluble in it. Another reason to use this aprotic solvent was the possibility of performing the Knoevenagel condensation and the subsequent reductive step in a one-pot synthesis, eliminating the need to isolate the intermediate **4**. Although the Knoevenagel condensation was studied using various catalysts²¹⁻²³ and even performed in water alone without a catalyst,²⁴ we found the classical catalyst piperidine to be the most suitable in this case.

At first, we investigated the necessary concentration of piperidine at ambient temperature. The amount of piperidine was critical during the condensation of the most reactive aldehyde **3b** so that the product **4b** could be isolated in high purity. One mole percent of piperidine was found to be sufficient for complete condensation without any decrease in purity or yield. The reaction time was extended to 24 hours for the less reactive aldehydes **3a** and **3c**. In general, the optimized reaction conditions (THF, 1% piperidine, rt, 24 h) were found to be applicable for all selected aldehydes **3a-o**, and yields of the isolated benzylidenemalononitriles **4a-d** were higher than 80%. Except for the benzylidenemalononitriles **4a** and **4b**, which were isolated for model study purposes, only the benzylidenemalononitriles **4c** and **4d** were isolated and characterized because no data for these analogs was previously published. Benzylidenemalononitriles **4e-o** were directly reduced to benzylmalononitriles **5** without an isolation of the intermediates **4**.



Scheme 2

The second step, the reduction of a C=C bond, was optimized using purified benzylidenemalononitriles **4a** and **4b**. Although it is possible to find references describing the C=C bond reduction of some benzylidenemalononitriles,²⁵⁻²⁸ we decided to use sodium cyanoborohydride as a new alternative reducing

agent for the electron deficient C=C bond in intermediates **4**. Some authors, when describing the reduction of heterocyclic systems with sodium cyanoborohydride, indicate that it might also be efficient in our system.²⁹⁻³¹ The first attempt to reduce **4a** or **4b** with sodium cyanoborohydride in THF at ambient temperature afforded only a mixture of compounds, but no desired benzylmalononitriles **5a** or **5b** were detected by HPLC/MS. When the same reaction was carried out in the presence of acetic acid, benzylmalononitriles **5a** and **5b** were the major products, and after work up, they were easily isolated by filtration. Next, we focused our effort on the preparation of benzylmalononitriles **5a** and **5b** directly from the corresponding aldehydes **3a** and **3b** without the need to isolate the intermediate benzylidenemalononitriles **4a** and **4b**. A simple one-pot procedure was developed as follows. After the first condensation step was completed, a THF solution containing sodium cyanoborohydride and acetic acid was added, and the resulting reaction mixture was continuously stirred for an additional three hours. The resulting benzylmalononitriles **5a-o** were then isolated by filtration or extraction and purified by recrystallization or chromatography. This one-pot synthetic strategy was applied for the preparation of all benzylmalononitriles **5a-o** with yields ranging between 37 and 70% over the two steps.

Several attempts to synthesize pyrazoles **2** from benzylmalononitriles **5a** and **5b** in a one-pot procedure were carried out. Because the cycloaddition reaction with hydrazine hydrate in boiling THF failed, it was obvious that the preceding isolation of benzylmalononitrile **5** is necessary. The cyclization proceeds in EtOH but was troublesome due to the formation of greasy products that were difficult to isolate when using the reported procedure for benzene-unsubstituted derivatives.³² Despite our difficulties using EtOH in the final step, MeOH was found to be a suitable solvent. Utilization of MeOH enabled to simplify the isolation of cycloaddition reaction products. The pyrazoles **2a-o**, prepared from corresponding benzylmalononitriles **5a-o** with hydrazine hydrate in boiling MeOH, were obtained in yields between 29 and 88%. Isolation of the pyrazoles **2a-l** was simple. After evaporation of MeOH, the residue was triturated with DCM or recrystallized from a mixture of MeOH and ethyl acetate. The attempts to isolate pure pyrazoles **2m-o** as a free base or a hydrochloride salt failed, although they were identified as part of the reaction mixture by HPLC-MS.

In the ¹³C NMR spectra of the isolated compounds, we observed an unusual overlap of carbon signals for pyrazole **2d**. The HSQC NMR spectrum revealed that carbon signals representing the meta and para position were overlapped, so the ¹³C NMR spectrum showed only 6 singlets instead of the expected 7 singlets. In addition to this result, another complication can occur when measuring the ¹³C NMR spectrum of pyrazole **2**. The pyrazole carbon signal around 149 ppm, common to all the pyrazoles we isolated, was difficult to observe in some derivatives. The signal is broadened probably due to tautomerism of the pyrazole ring; hence, the number of scans should be increased sufficiently.

Previous biochemical assays showed the ability of 4-aryloxy-1*H*-pyrazole-3,5-diamines **1** to inhibit the

enzymatic activity of cyclin-dependent kinases (CDKs), which are critical regulators of the cell cycle and some other cellular processes.⁶ Since the prepared pyrazoles **2a-l** contain structural moieties similar to derivatives **1** we decided to test them for CDK inhibition and antiproliferative activity. However, none of the prepared compounds inhibited the kinase CDK2/cyclin E, probably due to differences in conformation between **1** and **2**. Arylazo derivatives **1** are able to set almost planar conformation which was proven by co-crystallization of CAN508 with CDK2 or with CDK9.^{6,33} In contrast, our benzyl analogues probably adopt a less planar conformation due to the sp³ configuration of the carbon in the methylene group. Such molecules cannot enter the active site of CDKs and thus will not inhibit their catalytic activity.

Despite this result that 4-benzyl-1*H*-pyrazole-3,5-diamines **2a-l** are not CDK inhibitors, we tested their anticancer cytotoxicity under *in vitro* conditions in two cancer cell lines, K-562 (myeloid leukemia) and MCF-7 (breast adenocarcinoma). The rationale for performing the cytotoxicity assay was based on a hypothesis that the cytotoxicity of 4-arylazo-1*H*-pyrazole-3,5-diamines **1** found in our previous work can be mediated by interaction(s) with other cellular targets besides CDKs.⁶ However, the assays showed that all prepared compounds were not cytotoxic against the two cell lines. These results confirm that cytotoxicity of 4-arylazo-1*H*-pyrazole-3,5-diamines **1** is at least partially a consequence of CDK inhibition in cells.

A novel alternative one-pot procedure to afford benzylmalononitriles **5** from commercially available benzaldehydes **3** was developed. Sodium cyanoborohydride turned out to be an efficient reagent to reduce the electron deficient C=C bond in the benzylidenemalononitriles **4**. The choice of solvent is critical for the final step. The cycloaddition of hydrazine with the benzylmalononitriles **5** to give the desired benzylpyrazoles **2** works best in MeOH. All three steps were evaluated for various derivatives. None of the prepared pyrazoles **2a-l** showed antiproliferative activity against the cell lines K562 or MCF7.

EXPERIMENTAL

All starting materials used are commercially available. Melting points were determined on a Boetius stage. The LC/MS analyses were carried out on an UHPLC-MS system consisting of an Accela UHPLC chromatograph with a photodiode array detector and a TSQ Quantum Access triple quadrupole mass spectrometer (both Thermo Scientific, CA, USA), using a Nucleodur Gravity C18 column (Macherey-Nagel, 1.8 μm, 2.1 x 50 mm, Germany) at 30 °C and a flow rate of 800 μL/min. The APCI source operated at a discharge current of 5 μA, vaporizer temperature of 400 °C and capillary temperature of 200 °C. The ¹H and ¹³C NMR spectra were measured in DMSO-*d*₆ at 20 °C on a Bruker Avance 300 FT NMR spectrometer. Elemental analyses were performed using an EA 1108 Elemental Analyzer (Fison Instruments).

Typical procedure for the synthesis of 2-benzylidenemalononitriles (4)

The corresponding aldehyde **3** (5 mmol) and piperidine (0.05 mmol) were added to a solution of malononitrile (5 mmol) in THF (5 mL). The reaction mixture was stirred for 24 h at room temperature and then was diluted with water (25 mL). The precipitate was collected by filtration, washed with water and recrystallized from EtOH or a mixture of EtOH and water.

2-(4-Hydroxybenzylidene)malononitrile (4a)

Prepared from 4-hydroxybenzaldehyde. 0.80 g (94%), mp 188–189 °C (EtOH/H₂O). MS (-APCI, *m/z*): 169.0. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 6.96 (d, *J* = 8.6 Hz, 2 H), 7.88 (d, *J* = 8.6 Hz, 2 H), 8.27 (s, 1 H), 11.05 (bs, 1 H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 75.1, 114.2, 115.1, 116.6, 122.8, 133.9, 160.5, 163.9. Anal. Calcd for C₁₀H₆N₂O (170.17): C, 70.58; H, 3.55; N, 16.46. Found: C, 70.42; H, 3.61; N, 16.26.

2-(4-Nitrobenzylidene)malononitrile (4b)

Prepared from 4-nitrobenzaldehyde. 0.96 g (96%), mp 159–160 °C (EtOH). MS (+APCI, *m/z*): 198.9. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 8.13 (dd, *J* = 8.8, 1.8 Hz, 2 H), 8.42 (dd, *J* = 8.8, 1.8 Hz, 2 H), 8.72 (s, 1 H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 85.9, 112.5, 113.6, 124.4, 131.5, 136.7, 149.7, 159.3. Anal. Calcd for C₁₀H₅N₃O₂ (199.17); C, 60.31; H, 2.53; N, 21.10. Found: C, 60.45; H, 2.60; N, 21.18.

2-(2,6-Dimethylbenzylidene)malononitrile (4c)

Prepared from 2,6-dimethylbenzaldehyde. 0.89 g (98%), mp 78–80 °C (EtOH). MS (-APCI, *m/z*): 181.9. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 2.27 (s, 6 H), 7.18 (d, *J* = 7.5 Hz, 2 H), 7.31 (t, *J* = 7.5 Hz, 1 H), 8.85 (s, 1 H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 19.6, 90.4, 112.1, 112.9, 128.0, 130.4, 131.1, 135.8, 165.7. Anal. Calcd for C₁₂H₁₀N₂ (182.22); C, 79.10; H, 5.53; N, 15.37. Found: C, 79.22; H, 5.39; N, 15.56.

2-(2,6-Dichlorbenzylidene)malononitrile (4d)

Prepared from 2,6-dichlorbenzaldehyde. 0.89 g (80%), mp 73–74 °C (EtOH). MS (-APCI, *m/z*): 221.9, 223.9. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 7.57–7.73 (m, 3H), 8.85 (s, 1H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 93.1, 111.1, 112.1, 129.0, 129.2, 132.7, 133.5, 159.6. Anal. Calcd for C₁₀H₄Cl₂N₂ (223.06); C, 53.85; H, 1.81; N, 12.56. Found: C, 53.96; H, 1.99; N, 12.32.

Typical procedure for the synthesis of benzylmalononitriles (5)

The corresponding aldehyde **3** (5 mmol) and piperidine (0.05 mmol) were added to a solution of malononitrile (5 mmol) in THF (5 mL). The reaction mixture was stirred for 24 hours at room temperature, then a solution of acetic acid (0.6 mL) and sodium cyanoborohydride (5 mmol) in THF (15 mL) was added. After three hours of stirring at ambient temperature, THF was evaporated under reduced pressure and water (30 mL) was added to the residue. The precipitated solid was collected by filtration

and recrystallized from MeOH or a mixture of MeOH and water (method A). If a precipitate was not formed, the crude product was extracted with DCM (20 mL) and purified by the column chromatography (method B).

2-(4-Hydroxybenzyl)malononitrile (5a)

Prepared from 4-hydroxybenzaldehyde (method A). 0.54 g (63%), mp 173-176 °C (MeOH/H₂O). MS (-APCI, *m/z*): 171.0. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 3.19 (d, *J* = 6.7 Hz, 2 H), 4.99 (t, *J* = 6.8 Hz, 1 H), 6.75 (d, *J* = 8.4 Hz, 2 H), 7.16 (d, *J* = 8.6 Hz, 2 H), 9.49 (s, 1 H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 24.6, 34.1, 114.2, 115.4, 124.8, 130.5, 157.1. Anal. Calcd for C₁₀H₈N₂O (172.18); C, 69.76; H, 4.68; N, 16.27. Found: C, 69.45; H, 4.47; N, 16.01.

2-(4-Nitrobenzyl)malononitrile (5b)

Prepared from 4-nitrobenzaldehyde (method A). 0.51 g (51%), mp 153-154 °C (MeOH). MS (-APCI, *m/z*): 199.9. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 3.54 (d, *J* = 7.1 Hz, 2 H), 5.22 (t, *J* = 7.0 Hz, 1 H), 7.67 (d, *J* = 8.6 Hz, 2 H), 8.27 (d, *J* = 8.7 Hz, 2 H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 23.8, 33.9, 113.8, 123.8, 130.9, 142.5, 147.3. Anal. Calcd for C₁₀H₇N₃O₂ (201.18); C, 59.70; H, 3.51; N, 20.89. Found: C, 59.96; H, 3.23; N, 20.57.

2-(2,6-Dimethylbenzyl)malononitrile (5c)

Prepared from 2,6-dimethylbenzaldehyde (method B). 0.45 g (49%), mp 71-73 °C. MS (-APCI, *m/z*): 183.0. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 2.37 (s, 6 H), 3.44 (d, *J* = 8.2 Hz, 2 H), 4.99 (t, *J* = 8.2 Hz, 1 H), 7.04-7.15 (m, 3 H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 19.6, 21.8, 28.9, 114.2, 127.8, 128.5, 131.3, 137.4. Anal. Calcd for C₁₂H₁₂N₂ (184.24); C, 78.23; H, 6.57; N, 15.21. Found: C, 78.27; H, 6.61; N, 15.43.

2-(2,6-Dichlorobenzyl)malononitrile (5d)

Prepared from 2,6-dichlorobenzaldehyde (method A). 0.79 g (70%), mp 84-86 °C (MeOH/H₂O). MS (-APCI, *m/z*): 222.8. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 3.68 (d, *J* = 7.9 Hz, 2 H), 5.17 (t, *J* = 8.0 Hz, 1 H), 7.43 (t, *J* = 7.7 Hz, 1 H), 7.57 (d, *J* = 7.7 Hz, 2 H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 21.2, 30.6, 113.4, 129.0, 130.1, 131.1, 135.4. Anal. Calcd for C₁₀H₆Cl₂N₂ (225.07); C, 53.36; H, 2.69; N, 12.45. Found: C, 53.42; H, 2.78; N, 12.14.

2-(3-Nitrobenzyl)malononitrile (5e)

Prepared from 3-nitrobenzaldehyde (method A). 0.54 g (54%), mp 126-128 °C (MeOH). MS (-APCI, *m/z*): 199.9. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 3.56 (d, *J* = 7.3 Hz, 2 H), 5.22 (t, *J* = 7.2 Hz, 1 H), 7.72 (t, *J* = 8.1 Hz, 1 H), 7.86 (d, *J* = 7.7 Hz, 1 H), 8.22 (dd, *J* = 8.2, 1.3 Hz, 1 H), 8.34 (s, 1 H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 24.0, 33.7, 113.8, 122.9, 124.2, 130.2, 136.3, 136.9, 147.8. Anal. Calcd for C₁₀H₇N₃O₂ (201.18); C, 59.70; H, 3.51; N, 20.89. Found: C, 59.76; H, 3.38; N, 20.65.

2-(4-Methoxybenzyl)malononitrile (5f)

Prepared from 4-methoxybenzaldehyde (method B). 0.34g (40%), mp 80-81 °C. MS (-APCI, *m/z*): 185.0. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 3.26 (d, *J* = 6.7 Hz, 2 H), 3.75 (s, 3 H), 5.03 (t, *J* = 6.8 Hz, 1 H), 6.95 (d, *J* = 8.6 Hz, 2 H), 7.29 (d, *J* = 8.6 Hz, 2 H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 24.5, 33.9, 55.0, 114.0, 114.1, 126.5, 130.5, 158.9. Anal. Calcd for C₁₁H₁₀N₂O (186.21); C, 70.95; H, 5.41; N, 15.04. Found: C, 70.88; H, 5.63; N, 14.99.

2-(3-Hydroxybenzyl)malononitrile (5g)

Prepared from 3-hydroxybenzaldehyde (method B). 0.52 g (60%), mp 77-78 °C. MS (-APCI, *m/z*): 170.9. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 3.23 (d, *J* = 6.7 Hz, 2 H), 5.05 (t, *J* = 6.8 Hz, 1 H), 6.63 - 6.86 (m, 3 H), 7.05-7.26 (m, 1 H), 9.54 (s, 1 H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 24.3, 34.7, 114.2, 115.0, 116.2, 119.9, 129.7, 136.0, 157.5. Anal. Calcd for C₁₀H₈N₂O (172.18); C, 69.76; H, 4.68; N, 16.27. Found: C, 69.89; H, 4.47; N, 16.11.

2-(3-Fluorobenzyl)malononitrile (5h)

Prepared from 3-fluorobenzaldehyde (method B). 0.42 g (48%), mp < 65 °C. MS (-APCI, *m/z*): 172.9. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 3.38 (d, *J* = 6.9 Hz, 2 H), 5.14 (t, *J* = 7.1 Hz, 1 H), 7.09 - 7.31 (m, 3 H), 7.39-7.50 (m, 1 H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 24.0, 34.0, 113.9, 114.6, 114.9, 116.0, 116.3, 125.50, 125.53, 130.6, 130.7, 137.4, 137.5, 160.4, 163.6. Anal. Calcd for C₁₀H₇FN₂ (174.17); C, 68.96; H, 4.05; N, 16.08. Found: C, 68.81; H, 4.22; N, 16.35.

2-(4-Fluorobenzyl)malononitrile (5i)

Prepared from 4-fluorobenzaldehyde (method A). 0.55 g (64%), mp 107-110 °C (MeOH/H₂O). MS (-APCI, *m/z*): 172.9. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 3.34 (d, *J* = 6.8 Hz, 2H), 5.08 (t, *J* = 6.9 Hz, 1 H), 7.17-7.28 (m, 2 H), 7.37-7.48 (m, 2 H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 24.4, 33.7, 114.0, 115.3, 115.6, 130.91, 130.93, 131.4, 131.5, 160.2, 163.5. Anal. Calcd for C₁₀H₇FN₂ (174.17); C, 68.96; H, 4.05; N, 16.08. Found: 68.72; H, 4.17; N, 15.84.

2-(2,3,4,5,6-Pentafluorobenzyl)malononitrile (5j)

Prepared from 2,3,4,5,6-pentafluorobenzaldehyde (method A). 0.73 g (60%), mp 95-98 °C (MeOH/H₂O). MS (-APCI, *m/z*): 244.8. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 3.58 (d, *J* = 6.2 Hz, 2 H), 5.19 (t, *J* = 6.5 Hz, 1 H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 22.5, 22.7, 108.4 (t), 113.3, 135.8 (m), 138.3 (m), 139.3 (m), 141.8 (m), 143.9 (m), 146.3 (m). Anal. Calcd for C₁₀H₃F₅N₂ (246.14); C, 48.80; H, 1.23; N, 11.38. Found: C, 48.95; H, 1.36; N, 11.13.

2-(2-Chloro-6-fluorobenzyl)malononitrile (5k)

Prepared from 2-chloro-6-fluorobenzaldehyde (method A). 0.75 g (72%), mp 119-120 °C (MeOH). MS (-APCI, *m/z*): 206.9, 208.9. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 3.55 (dd, *J* = 7.3, 1.4 Hz, 2 H), 5.15 (t, *J* = 7.4 Hz, 1 H), 7.24-7.38 (m, 1 H), 7.39 - 7.53 (m, 2 H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 21.9, 26.37, 26.4, 113.5, 114.7, 115.0, 120.1, 120.4, 125.8, 125.9, 131.2, 131.3, 134.8, 134.9, 159.5, 162.8.

Anal. Calcd for C₁₀H₆ClFN₂ (208.62); C, 57.57; H, 2.90; N, 13.43. Found: C, 57.45; H, 3.01; N, 13.22.

2-(2-Fluorobenzyl)malononitrile (5l)

Prepared from 2-fluorobenzaldehyde (method B). 0.60 g (70%), mp 68-70 °C. MS (-APCI, *m/z*): 173.0. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 3.41 (d, *J* = 6.7 Hz, 2 H), 5.14 (t, *J* = 6.9 Hz, 1 H), 7.16 - 7.34 (m, 2 H), 7.36-7.55 (m, 2 H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 23.4, 28.02, 28.05, 113.8, 115.5, 115.7, 121.4, 121.6, 124.7, 124.8, 130.4, 130.5, 131.80, 131.84, 159.0, 162.2. Anal. Calcd for C₁₀H₇FN₂ (174.17); C, 68.96; H, 4.05; N, 16.08. Found: C, 68.84; H, 4.23; N, 16.20.

2-(2-Nitrobenzyl)malononitrile (5m)

Prepared from 2-nitrobenzaldehyde (method B). 0.97 g (97%), mp 85-86 °C. MS (-APCI, *m/z*): 200.0. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 3.73 (d, *J* = 7.5 Hz, 2 H), 5.23 (t, *J* = 7.4 Hz, 1 H), 7.57 - 7.74 (m, 2 H), 7.77-7.91 (m, 1 H), 8.16 (d, *J* = 8.2 Hz, 1 H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 23.3, 32.1, 113.8, 125.5, 129.5, 129.9, 133.2, 134.3, 148.5. Anal. Calcd for C₁₀H₇N₃O₂ (201.18); C, 59.70; H, 3.51; N, 20.89. Found: C, 59.57; H, 3.34; N, 20.61.

2-(3-Methoxybenzyl)malononitrile (5n)

Prepared from 3-methoxybenzaldehyde (method B). 0.35 g (37%), mp < 65 °C. MS (-APCI, *m/z*): 185.0. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 3.31 (d, *J* = 6.9 Hz, 2 H), 3.76 (s, 3 H), 5.11 (t, *J* = 7.2 Hz, 1 H), 6.85-7.01 (m, 3 H), 7.30 (t, *J* = 7.9 Hz, 1 H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 24.1, 34.5, 55.0, 113.2, 114.0, 115.0, 121.4, 129.7, 136.1, 159.3. Anal. Calcd for C₁₁H₁₀N₂O (186.21); C, 70.95; H, 5.41; N, 15.04. Found: C, 70.69; H, 5.28; N, 14.86.

2-(2-Methoxybenzyl)malononitrile (5o)

Prepared from 2-methoxybenzaldehyde (method B). 0.53 g (57%), mp < 65 °C. MS (-APCI, *m/z*): 185.0. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 3.30 (d, *J* = 6.9 Hz, 2 H), 3.81 (s, 3 H), 5.02 (t, *J* = 7.2 Hz, 1 H), 6.96 (td, *J* = 7.4, 0.9 Hz, 1 H), 7.05 (d, *J* = 8.0 Hz, 1 H), 7.24-7.41 (m, 2 H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ ppm 22.7, 29.9, 55.4, 111.0, 114.1, 120.4, 122.2, 129.6, 130.8, 157.3. Anal. Calcd for C₁₁H₁₀N₂O (186.21); C, 70.95; H, 5.41; N, 15.04. Found: C, 70.76; H, 5.21; N, 15.28.

Typical procedure for the synthesis of 4-aryl(methyl)-1*H*-pyrazole-3,5-diamines (2)

Hydrazine monohydrate (2.75 mmol) was added to a solution of the benzylmalononitrile **5** (2.5 mmol) in MeOH (17 mL). The reaction mixture was heated at 65°C for 8 hours. After the reaction was complete (TLC), the solvent was removed under reduced pressure, and the residue was suspended in DCM (20 mL). The precipitate was collected by filtration and recrystallized from a mixture of MeOH and ethyl acetate.

4-[(3,5-Diamino-1*H*-pyrazol-4-yl)methyl]phenol (2a)

Prepared from 2-(4-hydroxybenzyl)malononitrile **5a**. 0.31 g (60%), mp 203-205 °C. MS (+APCI, *m/z*): 205.8. ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm 3.37 (s, 2 H), 4.21 (NH), 6.61 (d, *J* = 8.2 Hz, 2 H), 7.00 (d,

$J = 8.2$ Hz, 2 H), 9.51 (OH). ^{13}C NMR (75 MHz, DMSO- d_6) δ ppm 26.1, 87.4, 114.7, 129.0, 132.4, 149.2, 155.0. Anal. Calcd for $\text{C}_{10}\text{H}_{12}\text{N}_4\text{O}$ (204.23); C, 58.81; H, 5.92; N, 27.43. Found: C, 58.56; H, 5.77; N, 27.09.

4-(4-Nitrobenzyl)-1H-pyrazole-3,5-diamine (2b)

Prepared from 2-(4-nitrobenzyl)malononitrile **5b**. 0.28 g (47%), mp 155-156 °C. MS (+APCI, m/z): 234.1. ^1H NMR (300 MHz, DMSO- d_6) δ ppm 3.65 (s, 2 H), 4.43 (bs, NH), 7.48 (d, $J = 8.7$ Hz, 2 H), 8.11 (d, $J = 8.7$ Hz, 2 H), 10.05 (bs, NH). ^{13}C NMR (75 MHz, DMSO- d_6) δ ppm 26.9, 85.4, 123.2, 129.3, 145.5, 149.5, 151.3. Anal. Calcd for $\text{C}_{10}\text{H}_{11}\text{N}_5\text{O}$ (233.23); C, 51.50; H, 4.75; N, 30.03. Found: C, 51.64; H, 4.33; N, 29.89.

4-(2,6-Dimethylbenzyl)-1H-pyrazole-3,5-diamine (2c)

Prepared from 2-(2,6-dimethylbenzyl)malononitrile **5c**. 0.15 g (29%), mp 170-173 °C. MS (+APCI, m/z): 217.1. ^1H NMR (300 MHz, DMSO- d_6) δ ppm 2.25 (s, 6 H), 3.48 (s, 2 H), 3.82 (bs, NH), 6.98-7.03 (m, 3 H). ^{13}C NMR (75 MHz, DMSO- d_6) δ ppm 19.8, 22.7, 83.5, 125.8, 128.0, 136.47, 136.52, 148.8. Anal. Calcd for $\text{C}_{12}\text{H}_{16}\text{N}_4$ (216.28); C, 66.64; H, 7.46; N, 25.90. Found: C, 66.47; H, 7.35; N, 26.12.

4-(2,6-Dichlorobenzyl)-1H-pyrazole-3,5-diamine (2d)

Prepared from 2-(2,6-dichlorobenzyl)malononitrile **5d**. 0.38 g (59%), mp 182-190 °C. MS (+APCI, m/z): 257.1; 259.0. ^1H NMR (300 MHz, DMSO- d_6) δ ppm 3.74 (s, 2 H), 4.26 (bs, NH), 7.25 (t, $J = 8.4$ Hz, 1 H), 7.44 (d, $J = 8.1$ Hz, 2 H). ^{13}C NMR (75 MHz, DMSO- d_6) δ ppm 24.2, 83.4, 128.6, 134.9, 135.8, 149.0. Anal. Calcd for $\text{C}_{10}\text{H}_{10}\text{Cl}_2\text{N}_4$ (257.12); C, 46.71; H, 3.92; N, 21.79. Found: C, 46.56; H, 3.73.; N, 22.04.

4-(3-Nitrobenzyl)-1H-pyrazole-3,5-diamine (2e)

Prepared from 2-(3-nitrobenzyl)malononitrile **5e**. 0.42 g (72%), mp 147-149 °C. MS (+APCI, m/z): 234.1. ^1H NMR (300 MHz, DMSO- d_6) δ ppm 3.67 (s, 2 H), 4.71 (bs, NH), 7.52 (t, $J = 7.7$ Hz, 1 H), 7.71 (d, $J = 7.7$ Hz, 1 H), 8.00 (d, $J = 7.7$ Hz, 1 H), 8.09 (s, 1 H). ^{13}C NMR (75 MHz, DMSO- d_6) δ ppm 26.5, 85.8, 120.5, 122.7, 129.4, 135.3, 145.3, 147.7, 149.7. Anal. Calcd for $\text{C}_{10}\text{H}_{11}\text{N}_5\text{O}$ (233.23); C, 51.50; H, 4.75; N, 30.03. Found: C, 51.73; H, 4.86; N, 29.85.

4-(4-Methoxybenzyl)-1H-pyrazole-3,5-diamine (2f)

Prepared from 2-(4-methoxybenzyl)malononitrile **5f**. 0.48 g (88%), mp 143-145 °C. MS (+APCI, m/z): 219.1. ^1H NMR (300 MHz, DMSO- d_6) δ ppm 3.43 (s, 2 H); 3.69 (s, 3 H); 4.22 (bs, NH); 6.79 (d, $J = 8.6$ Hz, 2 H); 7.13 (d, $J = 8.6$ Hz, 2 H), 9.98 (bs, NH). ^{13}C NMR (75 MHz, DMSO- d_6) δ ppm 26.1, 54.9, 87.2, 113.3, 129.0, 134.3, 149.1, 157.1. Anal. Calcd for $\text{C}_{11}\text{H}_{14}\text{N}_4\text{O}$ (218.26); C, 60.53; H, 6.47; N, 25.67. Found: C, 60.61; H, 6.58; N, 25.34.

3-[(3,5-Diamino-1H-pyrazol-4-yl)methyl]phenol (2g)

Prepared from 2-(3-hydroxybenzyl)malononitrile **5g**. 0.34 g (68%), mp 217-219 °C. MS (+APCI, m/z): 205.2. ^1H NMR (300 MHz, DMSO- d_6) δ ppm 3.44 (s, 2 H), 4.33 (bs, NH), 6.52 (dd, $J = 7.8, 1.7$ Hz, 1 H),

6.59 - 6.70 (m, 2 H), 7.01 (t, $J = 7.8$ Hz, 1 H), 9.56 (bs, OH). ^{13}C NMR (75 MHz, DMSO- d_6) δ ppm 27.0, 86.7, 112.4, 115.2, 119.0, 128.8, 143.8, 149.5, 157.3. Anal. Calcd for $\text{C}_{10}\text{H}_{12}\text{N}_4\text{O}$ (204.23); C, 58.81; H, 5.92; N, 27.43. Found: C, 58.87; H, 5.84; N, 27.36.

4-(3-Fluorobenzyl)-1H-pyrazole-3,5-diamine (2h)

Prepared from 2-(3-fluorobenzyl)malononitrile **5h**. 0.23 g (44%), mp 123-124 °C. MS (+APCI, m/z): 207.1. ^1H NMR (300 MHz, DMSO- d_6) δ ppm 3.52 (s, 2 H), 4.37 (bs, NH), 6.92 (td, $J = 8.6, 2.3$ Hz, 1 H), 7.01 (d, $J = 10.6$ Hz, 1 H), 7.08 (d, $J = 7.6$ Hz, 1 H), 7.19-7.30 (m, 1 H), 10.01 (bs, NH). ^{13}C NMR (75 MHz, DMSO- d_6) δ ppm 26.6, 86.3, 111.8, 112.1, 114.6, 114.9, 124.28, 124.31, 129.6, 129.7, 145.8, 145.9, 149.5 (bs), 160.6, 163.8. Anal. Calcd for $\text{C}_{10}\text{H}_{11}\text{FN}_4$ (206.22); C, 58.24; H, 5.38; N, 27.17. Found: C, 58.16; H, 5.22; N, 27.36.

4-(4-Fluorobenzyl)-1H-pyrazole-3,5-diamine (2i)

Prepared from 2-(4-fluorobenzyl)malononitrile **5i**. 0.26 g (52%), mp 150-152 °C. MS (+APCI, m/z): 207.1. ^1H NMR (300 MHz, DMSO- d_6) δ ppm 3.49 (s, 2 H), 4.36 (bs, NH), 7.04 (t, $J = 8.9$ Hz, 2 H), 7.16-7.33 (m, 2 H), 9.96 (bs, NH). ^{13}C NMR (75 MHz, DMSO- d_6) δ ppm 26.1, 86.8, 114.4, 114.6, 129.8, 129.9, 138.70, 138.73, 149.4, 158.8, 162.0. Anal. Calcd for $\text{C}_{10}\text{H}_{11}\text{FN}_4$ (206.22); C, 58.24; H, 5.38; N, 27.17. Found: C, 58.25; H, 5.57; N, 27.30.

4-(2,3,4,5,6-Pentafluorobenzyl)-1H-pyrazole-3,5-diamine (2j)

Prepared from 2-(2,3,4,5,6-pentafluorobenzyl)malononitrile **5j**. 0.23 g (33%), mp 200-202 °C. MS (+APCI, m/z): 279.1. ^1H NMR (300 MHz, DMSO- d_6) δ ppm 3.60 (s, 2 H), 4.24 (bs, NH), 10.10 (bs, NH). ^{13}C NMR (75 MHz, DMSO- d_6) δ ppm 14.6, 83.7, 115.1, (t), 135.6 (m), 137.4 (m), 138.0 (m), 139.9 (m), 143.3 (m), 145.7 (m), 149.2 (bs). Anal. Calcd for $\text{C}_{10}\text{H}_7\text{F}_5\text{N}_4$ (278.18); C, 43.18; H, 2.54; N, 20.14. Found: C, 43.25; H, 2.61; N, 20.06.

4-(2-Chloro-6-fluorobenzyl)-1H-pyrazole-3,5-diamine (2k)

Prepared from 2-(2-chloro-6-fluorobenzyl)malononitrile **5k**. 0.39 g (66%), mp 161-168 °C. MS (+APCI, m/z): 241.0, 243.0. ^1H NMR (300 MHz, DMSO- d_6) δ ppm 3.61 (d, $J = 2.0$ Hz, 2 H), 4.42 (bs, NH), 7.08-7.23 (m, 1 H), 7.24 - 7.39 (m, 2 H). ^{13}C NMR (75 MHz, DMSO- d_6) δ ppm 18.88, 18.92, 84.2, 114.2, 114.5, 125.4, 125.5, 126.4, 126.6, 128.3, 128.4, 133.95, 134.04, 149.0, 159.4, 162.6. Anal. Calcd for $\text{C}_{10}\text{H}_{10}\text{ClFN}_4$ (240.67); C, 49.91; H, 4.19; N, 23.28. Found: C, 49.85; H, 3.96; N, 23.39.

4-(2-Fluorobenzyl)-1H-pyrazole-3,5-diamine (2l)

Prepared from 2-(2-fluorobenzyl)malononitrile **5l**. 0.34 g (67%), mp 150-151 °C. MS (+APCI, m/z): 207.2. ^1H NMR (300 MHz, DMSO- d_6) δ ppm 3.55 (s, 2 H), 4.33 (bs, NH), 7.00-7.25 (m, 4 H), 9.98 (bs, NH). ^{13}C NMR (75 MHz, DMSO- d_6) δ ppm 19.77, 19.83, 84.2, 114.5, 114.8, 123.98, 124.02, 127.2, 127.3, 128.5, 128.7, 130.2, 130.3, 149.6, 158.9, 162.0. Anal. Calcd for $\text{C}_{10}\text{H}_{11}\text{FN}_4$ (206.22); C, 58.24; H, 5.38; N, 27.17. Found: C, 58.18; H, 5.33; N, 26.90.

ACKNOWLEDGEMENTS

We are grateful to grants MSM6198959216 from the Ministry of Education, Youth and Sports, and 204/08/0511 from the Czech Science Foundation.

REFERENCES

1. D. Fabbro, S. Ruetz, E. Buchdunger, S.W. Cowan-Jacob, G. Fendrich, J. Liebetanz, J. Mestan, T. O'Reilly, P. Traxler, B. Chaudhuri, H. Fretz, J. Zimmermann, T. Meyer, G. Caravatti, P. Furet, and P. W. Manley, *Pharmacol. Ther.*, 2002, **93**, 79.
2. L. N. Johnson, *Biochem. Soc. Trans.*, 2009, **37**, 627.
3. L. N. Johnson, *Q. Rev. Biophys.*, 2009, **42**, 1.
4. P. Cohen, *Nat. Rev. Drug Discov.*, 2002, **1**, 309.
5. E. Weisberg, P. W. Manley, S. W. Cowan-Jacob, A. Hochhaus, and J. D. Griffin, *Nat. Rev. Cancer*, 2007, **7**, 345.
6. V. Kryštof, P. Cankař, I. Fryšová, J. Slouka, G. Kontopidis, P. Džubák, M. Hajduch, J. Srovnal, W. F. de Azevedo, Jr., M. Orság, M. Paprskářová, J. Rolčík, A. Látr, P. M. Fischer, and M. Strnad, *J. Med. Chem.*, 2006, **49**, 6500.
7. J. Peng, Y. Zhu, J. T. Milton, and D. H. Price, *Gene. Dev.*, 1998, **12**, 755.
8. M. Sano, M. Abdellatif, H. Oh, M. Xie, L. Bagella, A. Giordano, L. H. Michael, F. J. DeMayo, and M. D. Schneider, *Nat. Med.*, 2002, **8**, 1310.
9. Y. Zhu, T. Pe'ery, J. Peng, Y. Ramanathan, N. F. Marshall, T. K. Marshall, B. A. Amendt, M. B. Mathews, and D. H. Price, *Gene. Dev.*, 1997, **11**, 2622.
10. H. S. Y. Mancebo, G. Lee, J. Flygare, J. Tomassini, P. Luu, Y. Zhu, J. Peng, C. Blau, D. Hazuda, D. Price, and O. Flores, *Gene. Dev.*, 1997, **11**, 2633.
11. D. E. MacCallum, J. Melville, S. Frame, K. Watt, S. Anderson, A. Gianella-Borradori, D. P. Lane, and S. R. Green, *Cancer Res.*, 2005, **65**, 5399.
12. R. Chen, M. J. Keating, V. Gandhi, and W. Plunkett, *Blood*, 2005, **106**, 2513.
13. M. E. M. Noble, J. A. Endicott, and L. N. Johnson, *Science*, 2004, **303**, 1800.
14. T. Tanaka, *Food Chem. Toxicol.*, 2006, **44**, 179.
15. E. Engel, H. Ulrich, R. Vasold, B. König, M. Landthaler, R. Süttinger, and W. Bäuml, *Dermatology*, 2008, **216**, 76.
16. B. Stanovnik and J. Svete, *Science of Synthesis*, 2002, **12**, 15.
17. J. J. Vaquero, L. Fuentes, J. C. Del Castillo, M. I. Perez, J. L. Garcia, and J. L. Soto, *Synthesis*, 1987, **33**.
18. V. J. Ram, M. Nath, B. Saraswat, and G. K. Patnaik, *Bioorg. Med. Chem. Lett.*, 1995, **5**, 1537.

19. F. Diez-Barra, A. de la Hoz, A. Moreno, and P. Sánchez-Verdú, [*Synthesis*, 1989, 391.](#)
20. B. C. Ranu, S. Banerjee, and R. Jana, [*Tetrahedron*, 2007, **63**, 776.](#)
21. B. C. Ranu and R. Jana, [*Eur. J. Org. Chem.*, 2006, 3767.](#)
22. J. Han, Y. Xu, Y. Su, X. She, and X. Pan, [*Catal. Commun.*, 2008, **9**, 2077.](#)
23. J. S. Yadav, B. V. S. Reddy, A. K. Basak, B. Visali, A. V. Narsaiah, and K. Nagaiah, [*Eur. J. Org. Chem.*, 2004, 546.](#)
24. M. L. Deb and P. J. Bhuyan, [*Tetrahedron Lett.*, 2005, **46**, 6453.](#)
25. J. C. Dunham, A. D. Richardson, and R. E. Sammelson, [*Synthesis*, 2006, 680.](#)
26. K. Nanjo, K. Suzuki, and M. Sekiya, *Chem. Pharm. Bull.*, 1977, **25**, 2396.
27. X. Zhu, H. Zou, P. Yuan, Y. Liu, L. Cao, and J. Cheng, [*J. Chem. Soc., Perkin Trans. 2*, 2000, 1857.](#)
28. S. J. Garden, C. R. W. Guimaraes, M. B. Correa, C. A. F. Oliveira, A. C. Pinto, and R. B. Alencastro, [*J. Org. Chem.*, 2003, **68**, 8815.](#)
29. E. Booker and U. J. Eisner, [*J. Chem. Soc., Perkin Trans. 1*, 1975, 929.](#)
30. R. O. Hutchins and N. R. Natale, [*Synthesis*, 1979, 281.](#)
31. P. Mulder, G. Litwinienko, S. Lin, P. D. MacLean, L. R. C. Barclay, and K. U. Ingold, [*Chem. Res. Toxicol.*, 2006, **19**, 79.](#)
32. S. M. Al-Mousawi, M. S. Moustafa, and M. H. Elnagdi, [*Heterocycles*, 2008, **75**, 1371.](#)
33. S. Baumli, manuscript in preparation.